M3814

DNA-PK-selective kinase inhibitor

oral efficacy in xenograft radiation models

undisclosed screening and optimization

Mol. Cancer Ther., Mar. 27, 2020

Merck KGaA, Darmstadt, DE

M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks